Off-label use of infliximab

Onder M., Salavastru C., Fritz K.

HAUTARZT, cilt.64, sa.10, ss.757-761, 2013 (SCI-Expanded) identifier identifier identifier

  • Yayın Türü: Makale / Tam Makale
  • Cilt numarası: 64 Sayı: 10
  • Basım Tarihi: 2013
  • Doi Numarası: 10.1007/s00105-013-2596-z
  • Dergi Adı: HAUTARZT
  • Derginin Tarandığı İndeksler: Science Citation Index Expanded (SCI-EXPANDED), Scopus
  • Sayfa Sayıları: ss.757-761
  • Gazi Üniversitesi Adresli: Hayır

Özet

Tumor necrosis factor alpha (TNF alpha) is a pro-inflammatory cytokine and a key mediator of inflammation. Several TNF alpha antagonists have been used therapeutically. One of them, infliximab, is a chimeric monoclonal antibody with anti-TNF alpha activity. Numerous studies have shown TNF alpha antagonists to be effective in treating psoriasis-particularly severe resistant forms-and arthritis. Additionally, several case reports and studies showing the effects of TNF alpha on new dermatologic indications have been published. The intention of this review is to summarize the new off-label uses of infliximab according to published data.